# Continuous peptide-based versus sequential standard polymeric enteral nutrition formula in critically ill patients with acute gastrointestinal injury: study protocol for a single-center, parallel-group randomized controlled trial

**Authors:** Yanhua Li, Youquan Wang, Ying Chen, Yuhan Zhang, Xinyu Li, Dong Zhang

PMC · DOI: 10.3389/fmed.2026.1761334 · Frontiers in Medicine · 2026-02-10

## TL;DR

This study compares two feeding formulas for critically ill patients with gut injury to determine which is better after initial recovery.

## Contribution

The study introduces a novel comparison of continuous peptide-based versus sequential standard polymeric formulas in post-acute gastrointestinal recovery.

## Key findings

- The primary outcome is the mean daily energy intake on day 7.
- The study will use intention-to-treat analysis to ensure robust results.

## Abstract

In critically ill patients with acute gastrointestinal injury (AGI), early administration of a peptide-based enteral formula (PBF) may be beneficial during the acute phase. Nevertheless, after gastrointestinal function improves, it remains unclear whether continuing a PBF or switching to a standard polymeric formula (SPF) is preferable.

To compare the efficacy and safety of continuing a PBF versus switching to an SPF from day 4 onward in critically ill patients with AGI whose gastrointestinal function has recovered or improved to AGI grade I by day 4.

Single-center, parallel-group, randomized, controlled, trial with 1:1 allocation, intention-to-treat analysis.

Three clinical units of the Department of Critical Care Medicine at the First Hospital of Jilin University (Changchun, China).

We will ultimately include 496 adult critically ill patients with AGI grade I–II who meet the eligibility criteria in the final analysis.

Continuous Peptide-Based Enteral Formula Group (PBF group): patients will receive continuous infusion of a PBF, initiated within 7 days of ICU admission. Sequential Standard Polymeric Enteral Formula Group (SPF group): patients will receive a PBF during the first 3 days in the ICU and will be transitioned to an SPF if the AGI grade is 0–I on ICU day 4.

The primary outcome is the mean daily energy intake on day 7 (kcal/kg/day). An intention-to-treat analysis will be used to assess this outcome to enhance the robustness of the results. Secondary outcomes and relevant process measures will be evaluated in accordance with the study protocol.

https://www.chictr.org.cn/showproj.html?pid=139513, Identifier ChiCTR2200056858.

## Full-text entities

- **Genes:** FABP2 (fatty acid binding protein 2) [NCBI Gene 2169] {aka FABPI, I-FABP}, AOC1 (amine oxidase copper containing 1) [NCBI Gene 26] {aka ABP, ABP1, DAO, DAO1, KAO, KDAO}, DAO (D-amino acid oxidase) [NCBI Gene 1610] {aka DAAO, DAMOX, OXDA}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** ischemia (MESH:D007511), Intestinal injury (MESH:D007410), septic (MESH:D001170), colonic mucosal injury (MESH:D003108), GI bleeding (MESH:D006471), regurgitation (MESH:D008944), Vomiting (MESH:D014839), nausea, vomiting (MESH:D020250), gastric (MESH:D013272), Abdominal Problems (MESH:D000007), hepatic or renal disease (MESH:D007674), obesity (MESH:D009765), organ dysfunction (MESH:D009102), muscle loss (MESH:D009135), Diarrhea (MESH:D003967), infections (MESH:D007239), liver and kidney dysfunction (MESH:D051437), Cancer (MESH:D009369), MI (MESH:D009104), gastrointestinal dysfunction (MESH:D005767), intolerance (MESH:D005633), chronic liver disease (MESH:D008107), reflux (MESH:D005764), Critically Ill (MESH:D016638), malnutrition (MESH:D044342), FI (MESH:D000073923), death (MESH:D003643), malabsorption (MESH:D008286), AGI (MESH:D001930), muscle (MESH:D019042)
- **Chemicals:** amino-acid (MESH:D000596), N-formyl-methionyl-leucyl-phenylalanine (MESH:D009240), D-lactate (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** start/stop

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929481/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12929481/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929481/full.md

---
Source: https://tomesphere.com/paper/PMC12929481